We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

17 hedge funds and large institutions have $2.27M invested in Traws Pharma in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

31% more funds holding

Funds holding: 13 → 17 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.02% less ownership

Funds ownership: 0.11% → 0.09% (-0.02%)

66% less capital invested

Capital invested by funds: $6.74M → $2.27M (-$4.46M)

Holders
17
Holders Change
+4
Holders Change %
+30.77%
% of All Funds
0.37%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
3
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$1.84M
2
Wells Fargo
Wells Fargo
California
+$257K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$45.6K
4
Renaissance Technologies
Renaissance Technologies
New York
+$15.5K
5
Victory Capital Management
Victory Capital Management
Texas
+$2.58K

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$934K
2
TCP
Tyndall Capital Partners
New York
-$452K
3
Citadel Advisors
Citadel Advisors
Florida
-$48K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$29.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$682K +$1.84M +2,141 New
TCP
2
Tyndall Capital Partners
New York
$524K -$452K -525 -24%
6CM
3
683 Capital Management
New York
$476K -$934K -1,085 -42%
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$205K – – –
KC
5
Kepos Capital
New York
$109K – – –
Wells Fargo
6
Wells Fargo
California
$95K +$257K +299 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$73K +$45.6K +53 +30%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$40K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$39K +$15.5K +18 +17%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$22K -$29.3K -34 -33%
UBS Group
11
UBS Group
Switzerland
$4K +$1.72K +2 +20%
Morgan Stanley
12
Morgan Stanley
New York
$1K – – –
PFGIA
13
Patriot Financial Group Insurance Agency
Massachusetts
$1K – – –
WCG
14
Weaver Consulting Group
California
$1K – – –
Victory Capital Management
15
Victory Capital Management
Texas
$1K +$2.58K +3 New
Citadel Advisors
16
Citadel Advisors
Florida
– -$48K -45 Closed
Bank of America
17
Bank of America
North Carolina
– +$861 +1 New
TRCT
18
Tower Research Capital (TRC)
New York
– +$861 +1 New

TRAW Hedge Fund Activity: Q3 2019 in Review

17 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2019, worth a combined $2.27M — down 66% from $6.74M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new TRAW positions and 1 closed out — a net gain of 4 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $1.84M. The largest seller was 683 Capital Management, cutting an estimated $934K.

  • 17 institutional investors held Traws Pharma (TRAW) as of Q3 2019, up from 13 in Q2 2019.
  • Funds reported $2.27M of Traws Pharma stock for Q3 2019, down 66% quarter-over-quarter.
  • 5 funds opened new Traws Pharma positions in Q3 2019 and 1 closed out, a net change of +4 holders.
  • The largest Traws Pharma buyer in Q3 2019 was Sabby Management, an estimated $1.84M added.
  • The largest Traws Pharma seller in Q3 2019 was 683 Capital Management, an estimated $934K sold.

Based on aggregated 13F filings for Q3 2019.